Role of SMARCA4 Mutations in Ovarian Carcinoma: Preliminary Data from a Laboratory-based Multigene Panel Testing Cohort.
SMARCA4 germline mutations are rare in the absence of SCCOHT.
SMARCA4 mutations do not predispose to epithelial ovarian cancer.
While the inclusion of SMARCA4 in MGPT did not significantly improve the diagnostic yield for ovarian cancer patients in this cohort, it should be included in the differential diagnosis for patients with SCCOHT.
Further investigation in larger ovarian cancer cohorts is necessary to determine the utility of SMARCA4 testing in other types of ovarian cancer
Authors: Jennifer Herrera-Mullar; Carrie Horton; Holly LaDuca; Andrew Castillo
Conference:
Western Association of Gynecologic Oncologists ( WAGO)